Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
Pulmonary alveolar proteinosis (PAP) is associated with defective macrophage clearance of surfactant. Here, the authors show that patients with PAP have altered cholesterol-to-phospholipid ratio in their surfactant, and that more importantly, statin therapy and reduction of cholesterol accumulation...
Main Authors: | Cormac McCarthy, Elinor Lee, James P. Bridges, Anthony Sallese, Takuji Suzuki, Jason C. Woods, Brian J. Bartholmai, Tisha Wang, Claudia Chalk, Brenna C. Carey, Paritha Arumugam, Kenjiro Shima, Elizabeth J. Tarling, Bruce C. Trapnell |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-05491-z |
Similar Items
-
Prevalence and healthcare burden of pulmonary alveolar proteinosis
by: Cormac McCarthy, et al.
Published: (2018-07-01) -
Pulmonary alveolar proteinosis: An autoimmune disease lacking an HLA association.
by: Kirsten Anderson, et al.
Published: (2019-01-01) -
Elucidating the Pathogenesis of Pulmonary Alveolar Proteinosis
by: Sallese, Anthony
Published: (2017) -
Therapy options in pulmonary alveolar proteinosis
by: Maurizio Luisetti, et al.
Published: (2010-08-01) -
Statin Pharmacotherapy in U.S. Nursing Homes
by: Mack, Deborah Sara
Published: (2020)